NDA Size Increases Should Be Cited By FDA To Defend Drug Safety - PhRMA
Executive Summary
FDA should defend the safety of prescription drugs by highlighting the increased size of average NDA packages, the Pharmaceutical Research and Manufacturers of America told a Center for Biologics Evaluation & Research "stakeholders" meeting Aug. 14.